Recruiting
Not applicable
Thumbtack Needle in the Treatment of NVP
Condition(s) studied
Nausea and Vomiting in Pregnancy (NVP)
Investigational drug(s) / intervention(s)
thumbtack needlesham thumbtack needle
thumbtack needle: As a kind of intradermal needle, thumbtack needle (TN) is a method of shallow puncture and long-term needle.After the TN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TN treatment. A total of 5 treatments were applied for a duration of 15 days.
sham thumbtack needle: The sham TN used in the sham TN group has no needle body and its appearance and shape are similar to the real TN. But it does not produce a needle-like effect.
The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days.
Study summary
This project intends to use multi-center, large-sample, randomized, controlled, blinded clinical trials to observe the clinical efficacy and safety of thumbtack needle (TN) on nausea and vomiting in pregnancy (NVP).
Eligibility
Inclusion Criteria:
* The mother\'s age is 20 \~ 45 years old, the gestational age is 6 \~ 12 weeks, and the ultrasound confirms that it is an intrauterine single or multiple pregnancy, and the weight loss is less than 10% compared with before pregnancy.
* Women diagnosed with moderate to severe NVP in the first trimester: the severity of NVP was determined by the PUQE score (see Table 1), and the PUQE score ranged from 3 \~ 15, \< 6 was mild NVP, 6 \~ 12 was moderate NVP, and ≥13 was severe NVP. PUQE score ≥ 6 may be included in this study.
* Women voluntarily sign the informed consent form.
Exclusion Criteria:
* Age \>20 years, and \<45 years.
* Gestational \> 6 weeks, or \<12 weeks.
* PUQE score \<6.
* frequent nausea and vomiting, weight loss of \>10% compared with before pregnancy; or symptoms such as listlessness, paleness, dry skin, sunken eye sockets, and a marked decrease in urine output (less than 400ml of urine in 24 hours or less than 5 times and a small amount of urine in 24 hours).
* At rest, body temperature \> 38°C, systolic blood pressure \< 90 mmHg or \> 140 mmHg, diastolic blood pressure \< 60 mmHg or \> 90 mmHg, heart rate ≥ 100 beats per minute, or oxygen saturation \< 95%.
* Urinalysis: urine ketones: +++ and above; or (and) urine protein: ++ and above.
* Blood biochemistry: serum potassium≤3.0mmol/L, serum sodium≤130mmol/L; or abnormal liver function: elevated liver enzymes ≥ 2 times the upper limit of normal; or renal dysfunction: elevated serum creatinine and urea nitrogen.
* Other digestive diseases that cause nausea and vomiting, such as gastrointestinal infections (with diarrhea), gastric ulcers (with epigastric pain or hematemesis), cholecystitis, biliary roundworms, pancreatitis (with abdominal pain, plasma amylase levels rise to 5 \~ 10 times normal), viral hepatitis (positive hepatitis virology, liver enzyme levels ≥ 1 000 U/L) or acute fatty liver during pregnancy, tumors of the digestive tract.
* Suffering from immune diseases such as systemic lupus erythematosus, scleroderma, dermatomyositis, IgG4-related diseases, immune nephropathy, etc.
* Have uncorrected diseases of the endocrine system, such as diabetes, Addison's disease, hyperthyroidism, hypothyroidism, thyroid tumors, adrenal tumors, etc.
* Suffering from neurological diseases such as migraine, neuromyelitis optica, epilepsy, neurologic tumors, etc.
* In the past 1 week, have taken antiemetic drugs such as ondansetron, metoclopramide (metoclopramide), promethazine, anti-vomiting Chinese medicine, etc.
* Monoamine oxidase inhibitors are used.
* Have received TN treatment in recent 3 months.
* Unwilling to sign the informed consent of this study.
Primary outcome measure(s)
- Score change of pregnancy unique quantification of emesis (PUQE) scale from baseline to day 15. — Baseline to day 15
PUQE scores ranged 3 to 15, with higher scores indicating a worse outcome. PUQE scores were evaluated before treatment and on days 3, 6, 9, 12, and 15 of treatment. The primary outcome measure was the change of PUQE score from baseline to day 15.
Trial sites (13)
| Facility | City | Region | Status |
| Jingzhou Hospital of Traditional Chinese Medicine |
Jingzhou |
Hubei |
Recruiting |
| Nanzhang County Traditional Chinese Medicine Hospital |
Nanzhang Chengguanzhen |
Hubei |
Recruiting |
| Qianjiang Central Hospital |
Qianjiang |
Hubei |
Recruiting |
| Qianjiang Maternal and Child Health Care Hospital |
Qianjiang |
Hubei |
Recruiting |
| Shiyan People's Hospital |
Shiyan |
Hubei |
Recruiting |
| Suizhou Maternal and Child Health Care Hospital |
Suizhou |
Hubei |
Recruiting |
| Wuhan Jinxin Gynecology and Obstetrics Hospital of Integrative Medicine |
Wuhan |
Hubei |
Recruiting |
| Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
Wuhan |
Hubei |
Recruiting |
| Xiangyang Hospital of Traditional Chinese Medicine |
Xiangyang |
Hubei |
Recruiting |
| Xiangyang Central Hospital |
Xiangyang |
Hubei |
Recruiting |
| Xiaogan Maternal and Child Health Care Hospital |
Xiaogan |
Hubei |
Recruiting |
| Dongchangfu District Maternal and Child Health Care Hospital of Liaocheng City |
Liaocheng |
Shandong |
Recruiting |
| Aksu Prefecture Maternal and Child Health Hospital |
Aksu |
Xinjiang |
Recruiting |